ARTL · Artelo Biosciences, Inc.
Artelo Biosciences Inc (ARTL)
What's happening
- ARTL is down 3.01% today, trading at $2.58. — Live quote
- It's trading within 3% of its 52-week low ($2.66). (Finnhub fundamentals)
- Volume today (789) is well below its 3-month average of 350,200. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $27.6M | $50.6M | $97.6M | $68.1M | $28.8M |
| P/E | -2.36 | -4.33 | -9.91 | -7.44 | -3.42 |
| Price/Book | 5.53 | 7.58 | -154.20 | -48.46 | 44.14 |
| ROE | -234.66% | -174.93% | 1555.29% | 651.35% | -1291.41% |
| ROA | -181.55% | -93.23% | -230.72% | -210.19% | -239.54% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -97.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ARTL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.5M | -$2.7M | -$3.1M | -$3.1M | -$2.4M | -$1.2M | -$2.5M | -$2.6M |
| Net income | -$2.4M | -$3.0M | -$3.1M | -$3.2M | -$2.4M | -$1.1M | -$2.4M | -$2.5M |
| EPS (diluted) | $-0.89 | $-4.00 | $-3.97 | $-16.86 | $-12.55 | $-2.10 | $-4.52 | $-0.78 |
| EPS (basic) | — | — | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.5M | $12.5M | $2.8M | $4.3M | $4.4M | $3.5M | $4.7M | $7.1M |
| Total liabilities | $1.5M | $5.8M | $4.1M | $4.9M | $5.8M | $2.9M | $1.8M | $775.0K |
| Stockholders' equity | $5.0M | $6.7M | -$1.3M | -$633.0K | -$1.4M | $652.0K | $2.9M | $6.4M |
| Total current assets | $4.4M | $10.4M | $695.0K | $1.8M | $2.2M | $1.4M | $2.6M | $5.0M |
| Total current liabilities | $1.5M | $5.8M | $4.0M | $4.9M | $5.7M | $2.8M | $1.8M | $697.0K |
| Cash & equivalents | — | $4.2M | $600.0K | — | — | — | — | — |
| Marketable securities (current) | — | — | — | $0 | $0 | $0 | $0 | $500.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | $0 | $500.0K |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Intangible assets | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | $0 | $26.0K | $11.0K | $46.0K | $18.0K | — | $0 | — |
| Common stock & paid-in capital | $4.0K | $1.0K | $1.0K | $2.0K | $1.0K | $3.0K | $1.0K | $3.0K |
| Retained earnings | -$68.4M | -$66.0M | -$63.0M | -$58.8M | -$55.7M | -$52.5M | -$50.1M | -$46.4M |
| Accumulated other comprehensive income (loss) | -$242.0K | -$246.0K | -$272.0K | -$277.0K | -$295.0K | -$227.0K | -$202.0K | -$218.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.0M | -$1.2M | -$2.9M | -$3.5M | -$514.0K | -$1.6M | -$2.6M | -$778.0K |
| Investing cash flow | — | — | $188.0K | -$250.0K | $0 | $0 | $500.0K | $4.2M |
| Financing cash flow | -$1.1M | $10.9M | $1.6M | $3.4M | $1.8M | $0 | $57.0K | $0 |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $570.0K | $401.0K | $800.0K | $432.0K | $150.0K | $192.0K | $605.0K | $209.0K |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$9.4M |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$9.4M |
| EPS (diluted) | $-12.52 | $-18.30 | $-3.14 | — | — |
| EPS (basic) | — | — | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M |
| Stockholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M |
| Total current assets | $695.0K | $2.6M | $11.0M | $18.3M | $24.6M |
| Total current liabilities | $4.0M | $1.8M | $1.3M | $998.0K | $1.0M |
| Cash & equivalents | $600.0K | — | — | $6.9M | $12.2M |
| Marketable securities (current) | — | $0 | $7.6M | $9.2M | $12.0M |
| Marketable securities (non-current) | — | $0 | $7.6M | $9.2M | $12.0M |
| Property, plant & equipment | — | — | — | — | — |
| Intangible assets | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Other non-current assets | — | — | — | $3.0K | $3.0K |
| Accrued liabilities | $11.0K | $0 | — | — | — |
| Common stock & paid-in capital | $2.0K | $1.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$63.0M | -$50.1M | -$40.3M | -$31.0M | -$20.9M |
| Accumulated other comprehensive income (loss) | -$272.0K | -$202.0K | -$203.0K | -$254.0K | -$18.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | -$6.1M |
| Investing cash flow | -$62.0K | $7.8M | $3.5M | $3.0M | -$3.4M |
| Financing cash flow | $6.9M | $112.0K | $567.0K | $0 | $14.1M |
| Share-based compensation | $1.1M | $818.0K | $1.0M | $2.5M | $1.5M |
| Purchases of investments | $0 | $481.0K | $13.7M | $12.7M | $6.1M |
| Sales/maturities of investments | — | — | $1.5M | $525.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ARTL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:33 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 8-K | 2026-10-09 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-17 | 8-K | 2026-07-17 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-26 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-11 | View on SEC.gov → |
Recent news
Headlines about ARTL (Artelo Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Yahoo Finance · 2026-10-07 -
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Yahoo Finance · 2026-09-23 -
Artelo Biosciences announces 1-for-9 reverse stock split
Seeking Alpha · 2026-08-27 -
Artelo Biosciences Announces Reverse Stock Split
Yahoo Finance · 2026-08-27 -
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Yahoo Finance · 2026-08-17 -
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Yahoo Finance · 2026-08-13 -
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
Yahoo Finance · 2026-07-22 -
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Yahoo Finance · 2026-07-16
No headlines in this category right now — try “All”.